AstraZeneca Announced Earlier Soliris Recommended For Approval In The Eu By Chmp For Children And Adolescents With Refractory Generalised Myasthenia Gravis
Portfolio Pulse from Charles Gross
AstraZeneca's Soliris has been recommended for marketing authorization in the EU for expanded use in treating refractory generalised myasthenia gravis (gMG) in children and adolescents aged 6-17 years. If authorized, Soliris would be the first and only targeted therapy approved for this patient group in the EU.
June 26, 2023 | 8:55 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's Soliris may receive EU marketing authorization for expanded use in treating refractory gMG in children and adolescents, potentially increasing the drug's market share.
The recommendation for marketing authorization in the EU for expanded use of Soliris in treating refractory gMG in children and adolescents would make it the first and only targeted therapy approved for this patient group in the EU. This could lead to increased market share and revenue for AstraZeneca.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100